

4D-710 in Adult Patients With Cystic Fibrosis

NCT05248230

Status	RECRUITING
Phase	Phase 2
Sponsor	4D Molecular Therapeutics
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (17)

- years and older
- Confirmed diagnosis of cystic fibrosis (CF) and CF lung disease including:
- Sweat chloride ≤ 60 mmol/L
- Mutation Status
- Bi-allelic mutations in the CFTR gene, or
- ... and 12 more (see full listing online)

Exclusion (18)

- Any prior gene therapy for any indication (Exception: mRNA-based or antisense oligonucleotide therapies are not exclusionary)
- Active Mycobacterium abscessus infection requiring ongoing treatment at Screening
- Active allergic bronchopulmonary aspergillosis requiring management with systemic corticosteroids or antifungal therapy
- Smoking (e.g. cigarettes, cigars, cannabis) or use of a vaping product during the 2 months prior to screening; must agree to not smoke or use vaping products during Screening and initial 24-month observation period.
- Contraindication to systemic corticosteroid therapy
- ... and 13 more (see full listing online)

Locations (20 total)

University of Alabama Child Health Research Unit, Birmingham, Alabama, United States
The University of Arizona, Tucson, Arizona, United States
University of California San Francisco, San Francisco, California, United States
... and 17 more locations